Informing pregnancy dose via target‐mediated drug disposition modeling and simulations for a recombinant human monoclonal antibody
CPT: Pharmacometrics & Systems Pharmacology · 2024
DOI: 10.1002/psp4.13250 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2024. Verfasst von Courtney Moc Willeford und 3 weiteren Autor:innen. Beteiligte Einrichtung: Certara USA, Radnor, Pennsylvania, USA. Hauptthemen laut MEDLINE: Models, Biological, Antibodies, Monoclonal. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Rallybio IPA, LLC.
Abstract (Originalsprache)
RLYB212 is a human monoclonal anti‐human platelet antigen (HPA)‐1a immunoglobulin gamma 1 in clinical development as a subcutaneous injection for the prevention of maternal alloimmunization to fetal HPA‐1a leading to fetal and neonatal alloimmune thrombocytopenia (FNAIT). This analysis developed a target‐mediated drug disposition (TMDD) model to simultaneously characterize RLYB212 pharmacokinetics (PK) and HPA‐1a‐positive platelet dynamics in HPA‐1b/b (HPA‐1a‐negative) volunteers. The model was then used to perform simulations to inform a dosing regimen in a phase II clinical study in pregnant women, where simulations accounted for physiological changes throughout pregnancy. Allometric scaling (0.75) for clearance and intercompartment transfer rate and volume (1) was included in the base model to account for variations in body weight. A 0.06 mg RLYB212 dose with a loading dose of 0.12 mg was identified as the optimal dosing regimen of RLYB212, which maintained exposures below the target upper boundary of ~10 ng/mL throughout pregnancy. This work presents an application of the TMDD model that advances the quantitative clinical pharmacology toolkit to understand monoclonal antibody PK in pregnancy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Certara USA, Radnor, Pennsylvania, USA.
- Rallybio, New Haven, Connecticut, USA.
ORCID-Profile: Courtney Moc Willeford, Krithika Shetty, Douglas Sheridan, Frank Engler
Förderung
- Rallybio IPA, LLC
Zitieren
APA
Moc Willeford, C., Shetty, K., Sheridan, D., & Engler, F. (2024). Informing pregnancy dose via target‐mediated drug disposition modeling and simulations for a recombinant human monoclonal antibody. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.13250
Vancouver
Moc Willeford C, Shetty K, Sheridan D, Engler F. Informing pregnancy dose via target‐mediated drug disposition modeling and simulations for a recombinant human monoclonal antibody. CPT: Pharmacometrics & Systems Pharmacology. 2024. doi:10.1002/psp4.13250
BibTeX
@article{MocWilleford2024,
author = {Moc Willeford, Courtney and Shetty, Krithika and Sheridan, Douglas and Engler, Frank},
title = {Informing pregnancy dose via target‐mediated drug disposition modeling and simulations for a recombinant human monoclonal antibody},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2024},
doi = {10.1002/psp4.13250}
}
EUVIMED